Illumina Inc (ILMN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

Loading...
Loading...
Summary:
Illumina reported its fourth quarter 2013 adjusted EPS of $0.45, $0.01 higher than the Zacks Consensus Estimate and 7.1% ahead of the year-ago number. Revenues surged 25.2% to $387.3 million, comfortably beating the Zacks Consensus Estimate of $380 million. We are impressed with the company's recently released market expansion plan which focuses on three major areas including reproductive health, onchology and emerging market. Further, expansion through strategic acquisitions, the most recent one being NextBio and partnerships with therapeutics and diagnostic services providers are expected to add value. However, government budget cut including NIH funding related issues and unfavorable currency were the major headwinds for Illumina during the reported quarter. The company also operates in a fiercely competitive landscape. Accordingly, we initiate Illumina at Neutral.


Overview:

San Diego, CA.-based Illumina Inc. ILMN is a life sciences company which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing- and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA.

Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies.

Illumina generates revenue from two segments Product and Service.

Product revenues (89.3% of total revenue in 2013) are primarily attributed to the sale of Microarrays and DNA Sequencing products. Product revenues consist of sales proceeds from the Consumables and Instruments segment used in genetic analysis. This includes reagents, flow cells, and BeadChips) based on the company's proprietary technologies. Service revenues (10.6%) include genotyping and sequencing services as well as instrument maintenance contracts.

Next-Generation Sequencing NGS

Illumina's portfolio of sequencing platforms represents a family of systems that are designed to meet the workflow, output, and accuracy demands of a full range of sequencing applications. The company's MiSeq sequencing system is a low-cost desktop sequencing system that provides individual researchers with rapid turnaround time, high accuracy and streamlined workflow. NextSeq 500, launched in Jan 2014, provides flexibility from whole genome sequencing to targeted panels in a desktop platform. The HiSeq 2500 sequencing system allows customers to sequence an entire human genome in approximately a day. HiSeq X Ten, announced in Jan 2014, is a set of ten ultra-high-throughput sequencers built for large-scale human whole-genome sequencing with the ability to generate 1.8 terabases of DNA sequence per sequencer in less than three days.

MicroArrays

As a complement to next-generation sequencing, microarrays offer a cheaper, faster and advanced technology when genetic content is already known. The information content of microarrays is fixed and reproducible. Microarrays provide repeatable, standardized assays for certain subsets of nucleotide bases within the overall genome.


Illumina Inc ILMN: Read the Full Research Report

ILLUMINA INC ILMN: Free Stock Analysis Report

To read this article on Zacks.com click here.
Loading...
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...